Ovarian cancer is an extremely deadly disease characterised by an abnormal growth of ovarian, fallopian tube or primary peritoneal tissue with malignant tumours spreading beyond the site of origin into the peritoneal cavity and affecting the organs within (e.g. the spleen, bowel mesentery and liver). There were nearly 300,000 new cases of ovarian cancer worldwide in 2018 [World Cancer Research Fund]. For most patients, surgery is the first line of treatment. This is usually followed by chemotherapy and typically devastating side effects including hair loss, nausea, vomiting, appetite loss, pain, weakened immunity and fatigue. We are developing #Oncojans, a promising new class of drug-loaded particles, designed to precisely target and gain entry to cancer cells. In the tumours, they slowly release drugs at the point of need whilst sparing healthy tissue. Early preclinical studies for #BMT101, our lead ovarian cancer candidate, compared to the clinical standard of care, Taxol®, have shown very encouraging results including over 10-fold increases in drug concentration in tumours, 65-fold reductions in tumour burden, doubling of median survival and loss of toxicity. #BMT101 and future engineered #Oncojans could be transformational in the treatment of cancer patients.